ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 959

A Disintegrin and Metalloprotease -17 Is Overexpressed on Rheumatoid Arthritis Osteoblasts and Is Regulated with TNF-α Stimulation

Hidekazu Furuya, Takeo Isozaki, Shinichiro Nishimi, Airi Nishimi, Takahiro Tokunaga, Kuninobu Wakabayashi and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Osteoblasts, rheumatoid arthritis (RA) and tumor necrosis factor (TNF)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: A disintegrin and metalloprotease family proteins (ADAMs) have been reported to be involved in a number of inflammatory conditions. We have previously reported a disintegrin and metalloprotease- 17 (ADAM-17) is expressed in rheumatoid arthritis (RA) synovial fluids and synovial tissues, and is increased compared to osteoarthritis (OA) synovial fluids. Cells involved in bone formation express a variety of cytokines and osteoblasts appear to be major regulators of bone remodeling in RA. The association between ADAM-17 expression and osteoblasts is unclear. Here, we examine the expression of ADAM-17 in RA osteoblasts.

Methods: RA human osteoblasts (HOB) isolated from femora of RA patients were incubated. RA-HOB were stimulated with 25ng/ml tumor necrosis factor (TNF)-α at 4 hours, and messanger RNA (mRNA) was collected. ADAM-17 mRNA expression was examined using quantitative polymerase chain reaction (qPCR). To examine the expression of ADAM-17 in TNF-α stimulated RA-HOB conditioned medium, RA-HOB were stimulated with 0.25 ng/ml, 2.5 ng/ml and 25 ng/ml TNF-α at 24 hours and measured using enzyme linked immunosorbent assay (ELISA). To determine ADAM-17 expression in RA-HOB lysate, western brotting (WB) was also performed. Finally, to confirm the presence of ADAM-17 on RA osteoblasts, immunostaining was performed.

Results: ADAM-17 was expressed in TNF-α stimulated RA-HOBconditioned medium which was significantly higher compared to non-stimulated (NS) RA-HOB conditioned medium (mean ± SEM; 171 ± 4 pg/ml and 310 ± 21 pg/ml , respectively , p<0.05). Furthermore TNF-α was induced dose-dependent secretion of ADAM-17 levels from RA-HOB (mean±SEM; NS: 171 ± 4 pg/ml , TNF-α 0.25 ng/ml: 255 ± 15 pg/ml, TNF-α 2.5ng/ml: 234 ± 7 pg/ml, TNF-α 25 ng/ml: 310 ± 21 pg/ml, p<0.05). We found that ADAM-17 mRNA in TNF-α stimulated RA-HOB was 70 times elevated compared with in non-stimulated RA-HOB (p<0.05). Additionally, we also found that ADAM-17 expression on RA-HOB was inducible by TNF-α by using immunostaining and WB.

Conclusion: We have reported that ADAM-17 is involved in angiogenesis in synovial tissue of RA. In this study, we showed the expression of ADAM-17 in RA osteoblasts, suggesting the possibility that it plays an important role in bone destruction in inflammatory desease such as RA.


Disclosure: H. Furuya, None; T. Isozaki, None; S. Nishimi, None; A. Nishimi, None; T. Tokunaga, None; K. Wakabayashi, None; T. Kasama, None.

To cite this abstract in AMA style:

Furuya H, Isozaki T, Nishimi S, Nishimi A, Tokunaga T, Wakabayashi K, Kasama T. A Disintegrin and Metalloprotease -17 Is Overexpressed on Rheumatoid Arthritis Osteoblasts and Is Regulated with TNF-α Stimulation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-disintegrin-and-metalloprotease-17-is-overexpressed-on-rheumatoid-arthritis-osteoblasts-and-is-regulated-with-tnf-%ce%b1-stimulation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-disintegrin-and-metalloprotease-17-is-overexpressed-on-rheumatoid-arthritis-osteoblasts-and-is-regulated-with-tnf-%ce%b1-stimulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology